Ironwood Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, IRWD, Ironwood Pharmaceuticals Inc, priceseries

Ironwood Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
11.18
Close
11.51
High
11.56
Low
11.15
Previous Close
11.21
Daily Price Gain
0.30
YTD High
12.11
YTD High Date
Jan 4, 2022
YTD Low
10.13
YTD Low Date
Feb 17, 2022
YTD Price Change
-0.44
YTD Gain
-3.68%
52 Week High
14.27
52 Week High Date
Aug 12, 2021
52 Week Low
10.02
52 Week Low Date
Apr 12, 2021
52 Week Price Change
1.30
52 Week Gain
12.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 8. 2017
13.06
Feb 24. 2017
13.74
11 Trading Days
5.21%
Link
LONG
May 9. 2017
14.18
May 30. 2017
15.04
14 Trading Days
6.06%
Link
LONG
Apr 9. 2018
13.28
Apr 24. 2018
14.31
11 Trading Days
7.72%
Link
LONG
Jun 28. 2018
15.86
Jul 18. 2018
16.66
13 Trading Days
5.05%
Link
LONG
Jan 4. 2019
9.21
Jan 22. 2019
10.21
11 Trading Days
10.85%
Link
LONG
Mar 29. 2019
11.32
Apr 9. 2019
12.08
7 Trading Days
6.71%
Link
LONG
Oct 28. 2019
9.39
Dec 2. 2019
11.89
24 Trading Days
26.62%
Link
LONG
Dec 12. 2019
12.62
Dec 27. 2019
13.34
10 Trading Days
5.68%
Link
LONG
Nov 3. 2020
9.93
Nov 25. 2020
11.63
16 Trading Days
17.17%
Link
LONG
May 12. 2021
11.16
May 25. 2021
11.94
9 Trading Days
6.98%
Link
LONG
Jun 18. 2021
11.72
Jul 2. 2021
12.65
10 Trading Days
7.90%
Link
Company Information
Stock Symbol
IRWD
Exchange
NasdaqGS
Company URL
http://www.ironwoodpharma.com
Company Phone
617-621-7722
CEO
Peter M. Hecht
Headquarters
Massachusetts
Business Address
301 BINNEY STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001446847
About

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. It discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.

Description

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading